- Home
- AKAM vs UTHR Comparison
AKAM vs UTHR Comparison
Compare AKAM & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKAM
- UTHR
- Stock Information
- Founded
- AKAM 1998
- UTHR 1996
- Country
- AKAM United States
- UTHR United States
- Employees
- AKAM N/A
- UTHR N/A
- Industry
- AKAM Business Services
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- AKAM Consumer Discretionary
- UTHR Health Care
- Exchange
- AKAM Nasdaq
- UTHR Nasdaq
- Market Cap
- AKAM 14.0B
- UTHR 16.1B
- IPO Year
- AKAM 1999
- UTHR 1999
- Fundamental
- Price
- AKAM $91.01
- UTHR $358.93
- Analyst Decision
- AKAM Buy
- UTHR Buy
- Analyst Count
- AKAM 20
- UTHR 14
- Target Price
- AKAM $115.37
- UTHR $378.36
- AVG Volume (30 Days)
- AKAM 1.5M
- UTHR 301.3K
- Earning Date
- AKAM 02-20-2025
- UTHR 02-19-2025
- Dividend Yield
- AKAM N/A
- UTHR N/A
- EPS Growth
- AKAM 2.15
- UTHR 25.10
- EPS
- AKAM 3.38
- UTHR 22.72
- Revenue
- AKAM $3,966,246,000.00
- UTHR $2,756,200,000.00
- Revenue This Year
- AKAM $6.61
- UTHR $26.19
- Revenue Next Year
- AKAM $6.72
- UTHR $10.79
- P/E Ratio
- AKAM $26.92
- UTHR $15.80
- Revenue Growth
- AKAM 5.92
- UTHR 25.04
- 52 Week Low
- AKAM $84.70
- UTHR $208.62
- 52 Week High
- AKAM $129.17
- UTHR $417.82
- Technical
- Relative Strength Index (RSI)
- AKAM 39.51
- UTHR 45.95
- Support Level
- AKAM $89.55
- UTHR $357.55
- Resistance Level
- AKAM $91.92
- UTHR $370.48
- Average True Range (ATR)
- AKAM 2.13
- UTHR 8.55
- MACD
- AKAM -0.39
- UTHR 0.60
- Stochastic Oscillator
- AKAM 27.34
- UTHR 37.37
About AKAM Akamai Technologies Inc.
Akamai operates a content delivery network, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,100 points of presence in more than 1,000 cities worldwide. The firm also offers security and cloud computing for its customers, and those businesses have grown to be bigger than the legacy CDN.
About UTHR United Therapeutics Corporation
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.